Objective Capital Management LLC Purchases Shares of 10,110 Edwards Lifesciences Co. (NYSE:EW)

Objective Capital Management LLC purchased a new stake in Edwards Lifesciences Co. (NYSE:EW) during the 3rd quarter, Holdings Channel.com reports. The institutional investor purchased 10,110 shares of the medical research company’s stock, valued at approximately $667,000.

Several other institutional investors also recently modified their holdings of EW. Crewe Advisors LLC purchased a new position in Edwards Lifesciences during the 1st quarter worth approximately $28,000. First Community Trust NA purchased a new position in shares of Edwards Lifesciences during the 2nd quarter valued at $29,000. Webster Bank N. A. purchased a new position in shares of Edwards Lifesciences during the 2nd quarter valued at $39,000. Versant Capital Management Inc grew its holdings in shares of Edwards Lifesciences by 206.3% during the 2nd quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock valued at $45,000 after acquiring an additional 326 shares in the last quarter. Finally, HHM Wealth Advisors LLC purchased a new position in shares of Edwards Lifesciences during the 2nd quarter valued at $55,000. Institutional investors own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on EW. Daiwa America cut shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 30th. Morgan Stanley restated an “equal weight” rating and set a $70.00 price target on shares of Edwards Lifesciences in a report on Friday, October 11th. Sanford C. Bernstein upgraded shares of Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a report on Monday, October 28th. Citigroup decreased their price objective on shares of Edwards Lifesciences from $83.00 to $77.00 and set a “buy” rating for the company in a report on Tuesday, October 1st. Finally, Oppenheimer reiterated an “outperform” rating and issued a $90.00 price objective on shares of Edwards Lifesciences in a report on Thursday, September 12th. Seventeen equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat, Edwards Lifesciences presently has a consensus rating of “Hold” and a consensus target price of $75.67.

Insider Activity

In other news, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the transaction, the insider now owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the sale, the insider now owns 198,526 shares of the company’s stock, valued at $13,084,848.66. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total transaction of $347,550.00. Following the completion of the sale, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,262,521.36. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 41,250 shares of company stock valued at $2,746,988. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock traded up $0.39 on Friday, reaching $66.23. 3,088,441 shares of the stock were exchanged, compared to its average volume of 5,173,085. The firm has a fifty day moving average price of $67.59 and a two-hundred day moving average price of $76.96. The stock has a market cap of $39.90 billion, a PE ratio of 9.56, a PEG ratio of 3.70 and a beta of 1.12. The company has a current ratio of 3.71, a quick ratio of 2.87 and a debt-to-equity ratio of 0.08. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting analysts’ consensus estimates of $0.67. The business had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 22.56%. The firm’s revenue for the quarter was up 8.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.59 earnings per share. Sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.57 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.